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Age-related macular degeneration (AMD) is the leading cause of blindness in people over age 55 in the U.S. and
the developed world. This condition leads to the progressive impairment of central visual acuity. There are
significant limitations in the understanding of disease progression in AMD as well as a lack of effective methods of
treatment. Lately, there has been considerable enthusiasm for application of stem cell biology for both disease
modeling and therapeutic application. Human embryonic stem cells and induced pluripotent stem cells (iPSCs)
have been used in cell culture assays and in vivo animal models. Recently a clinical trial was approved by FDA to
investigate the safety and efficacy of the human embryonic stem cell-derived retinal pigment epithelium (RPE)
transplantation in sub-retinal space of patients with dry AMD These studies suggest that stem cell research may
provide both insight regarding disease development and progression, as well as direction for therapeutic
innovation for the millions of patients afflicted with AMD.
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Age-related macular degeneration (AMD) is a devastat-
ing neurodegenerative disease and leading cause of
blindness in people over 55 years of age that affects a
central nervous system tissue, the retinal pigmented epi-
thelium (RPE) [1]. More than 11 million Americans over
the age of 50 are affected by AMD, and with an aging
population, this number will almost double by 2050 [2].
AMD is a multifactorial disease and its pathogenesis re-
mains largely unknown, implying a complex interaction
of genetic, environmental, metabolic and functional fac-
tors [3]. Clinically, AMD leads to the impairment of cen-
tral visual acuity that is required for daily tasks such as
reading, writing, driving, and recognizing faces, import-
ant for independent living. AMD occurs in two general
forms, dry and wet. The dry form of AMD is characterized
by polymorphic deposits called drusen that accumulate
between the RPE and Bruch’s membrane [4]. The wet* Correspondence: Ncg8@georgetown.edu
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reproduction in any medium, provided the orform is accompanied by choroidal neovascularization with
subsequent formation of a disciform scar. Affected indi-
viduals may lose vision in both atrophic (dry) and the
neovascular (wet) forms of AMD, however dry AMD is
significantly more common, accounting for some 90% of
total reported cases [5]. Dry AMD can transform into the
wet form in approximately 10% of the patients, with dev-
astating neovascularization-induced central vision loss [5].
There is currently no curative treatment for patients af-
fected with AMD, with the best attempts seeking to fore-
stall further degeneration at the retina [6]. Vitamin
supplementation is recommended and is modestly benefi-
cial for a small population of patients [7]. For the wet form
of AMD anti-vascular endothelial growth factor (VEGF)
therapy is applicable, however, the therapy is often admin-
istrated after significant damage has already been induced
to the retina [8]. Consequently, the need for developing ef-
fective treatments to improve outcomes for patients with
AMD is pressing [9]. Since the development of human
embryonic stem cell lines in 1998 [10] and the advent of
induced pluripotent stem cells [11,12] there has been en-
thusiasm in the scientific community for the potentiall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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AMD [13-18].
Stem cell biology can offer profound insight into the
mechanisms of AMD [19] and can provide new ap-
proaches for autologous cell-based therapy in AMD as
supported by the recently FDA approved clinical trial
(NCT01344993). Generation of RPE derived from patient-
specific induced pluripotent stem (iPS) cells may offer the
ability to recapitulate the disease state and screen new
therapeutics, improving upon the limited treatment strat-
egies currently available to afflicted patients. This review
will examine the breakthroughs and limitations of utilizing
stem cells for disease modeling and therapeutic applica-
tion in age-related macular degeneration.
AMD: disease progression and etiology
Impairment in RPE functions in AMD induces loss of cen-
tral vision at the macula as a result of photoreceptor de-
generation [1]. RPE comprises a monolayer of pigmented
cells with the apical membrane facing the light-sensitive
outer segments of photoreceptors and the basolateral
membrane facing the fenestrated capillaries of the choroid
[20,21]. It plays many crucial roles in the retina including
formation of blood/retina barrier by tight junctions, trans-
portation of nutrients such as glucose or vitamin A from
blood to the photoreceptors, conveyance of water from
subretinal space to the blood, establishment of immune
privilege of the eye, maintenance of ion composition in
the subretinal space, light absorption, isomerization of ret-
inal in the visual cycle, secretion of growth factors, and
phagocytosis of the outer segments of the photoreceptors
[22,23]. Due to their high metabolic activity, RPE cells are
constantly subjected to oxidative stress and high levels of
peroxidized lipid membranes [24]. Extended exposure to
oxidative stress can disrupt RPE tight junctions, inducing
the breakage of the blood barrier and producing abnormal
membrane bleb structures [25,26]. Furthermore, impair-
ment of RPE function in dry AMD can induce formation
of abnormal extracellular deposits called drusen that accu-
mulate between the RPE and Bruch’s membrane [4].
Drusen, the clinical hallmark of AMD, consist of patho-
logical extracellular deposits of degenerative material
[4,27-31]. Drusen contain lipid and carbohydrate deposits,
and have shown to include elements from both intracellu-
lar and extracellular sources. For example, integrins, lipo-
proteins, ubiquitin, inhibitor of metalloproteinase 3,
advanced glycation end products, beta amyloid, fibronec-
tin, and vitronectin have been identified in drusen
[30,32-34]. Extracellular products include amyloid compo-
nents, apolipoprotein E, factor X, immunoglobulin lambda
chains, complement components, like the C1-q complex,
late stage-activated complement components such as
C5b-9 complex, and major histocompatibility complex
(MHC) class II antigens [35]. Intracellular componentsare mainly derived from RPE and consist of cellular and
basal lamina fragments, lipofuscin and melanin, organelles
[36]. Some of the components of drusen are found in
non-occular diseases. Similarities are found with amyloid-
osis, elastosis, and glomerular basement membrane dis-
ease [37]. Amyloid beta, a waste product that accumulates
in the CNS with aging and Alzheimer’s Disease is a key
component of drusen. Increased accumulation of amyloid
beta with aging is found along Bruch’s membrane, blood
vessels, and in the photoreceptor outer segment [38].
Genetic factors are now considered as reliable bio-
markers to predict the risk of developing AMD, poten-
tial for disease severity and likelihood of progression
[39]. Genetic studies of AMD determined by candidate
gene approaches and genome wide association studies
demonstrate the involvement of an inflammatory com-
ponent [40]. Polymorphisms on chromosome 1 in com-
plement factor H (CFH) [41], complement 2 (C2),
complement factor B (CFB), complement 3 (C3), comple-
ment factor H-related gene (CFHR1) and complement fac-
tor I (CFI) are associated with increased risk of developing
AMD [42-48]. Furthermore, polymorphisms on chromo-
some 10 in ARMS2 (Age-related Maculopathy Susceptibil-
ity 2) [49] and the HTR1A serine peptidase 1 (HTRA1)
genes predispose to wet AMD [49-52]. Polymorphisms in
Apolipoprotein E (APOE), a component of drusen and a
gene involved in lipid metabolism, appear to increase sus-
ceptibility to AMD [41,53,54]. Proteins with major roles in
regulation of plasma lipids, such as hepatic triglyceride
lipase (HL) and the cholesteryl ester transfer protein
(CETP), as well as nearby markers of the inhibitor of
metalloproteinase 3 (TIMP3) gene are also associated
with an increased risk of AMD [40]. In addition, poly-
morphisms in VEGFA, a factor involved in angiogen-
esis, were shown to increase the risk of AMD [55].
Interestingly, there may also be a role for maternally
inherited mitochondrial DNA (mtDNA) specifically
the genes encoding for the various subunits involved
in oxidative phosphorylation. Inherited variants located
in the mtDNA T2 haplogroup, characterized by 2 vari-
ants in the complex I gene, have also been associated
with advanced AMD [56]. In addition, other variants
associated with mitochondrial haplogroup J, T and U
have also been associated with AMD [57,58].
A genetic condition referred as Stargardt disease is
caused by a mutation in the ABCA4 gene also recapit-
ulates the symptoms of macular degeneration but pre-
sents with much earlier onset, resulting in severe
visual impairment and loss of central vision before the
age of 20 [59]. Stargardt disease points to a significant
genetic component that likely plays a role in develop-
ment of AMD given that patients may progress later
in life depending on variable environmental factors
[3,39,59-61].
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environmental and epigenetic factors also play an im-
portant role in the etiology of AMD. Gene expression
during ocular development appears to be greatly im-
pacted by the epigenetics, with respect to cell types in
both the lens and retina, thus having implications ran-
ging from early stages of disease to propensity for
neovascularization during progression [62]. Concord-
ance studies with monozygotic twins have found that
nutritional and behavioral factors that influence epigen-
etics, such as vitamin D intake and smoking history,
confer greater likelihood of developing AMD [63]. These
environmental factors have been shown to significantly
alter epigenetic regulation, such as methylation and
acetylation, and therefore may confer a variable gene ex-
pression profile despite identical genetic information.
Most recently, a study by Wei et al. showed that
hypomethylation of IL17RC increases levels of circulat-
ing gene products, mainly inflammatory chemokines and
cytokines, implicating both epigenetics and certain immune
mediators in the pathogenesis of AMD [64] . Furthermore,
a recent study showed that Glutathione S-transferase
isoforms mu1 (GSTM1) and mu5 (GSTM5) undergo epi-
genetic repression in AMD RPE/choroid, which may in-
crease susceptibility to oxidative stress in the retinas of
AMD donors [65]. Another study showed that epigenetic
factors regulate clusterin/APOJ expression, one of the pro-
teins in drusen [65,66]. This continues to be an area of ex-
ploration, as the subject of epigenetics in AMD was
recently thoroughly reviewed [67] and the field will un-
doubtedly continue to expand.
AMD disease modeling
Given the complex dynamics of AMD, there have been
considerable challenges in the development of an animal
model that accurately recapitulates many of the charac-
teristics of human AMD. This is, at least in part due to
human genetic polymorphisms [68] and long-term ex-
posure to environmental factors [69] that induce epigen-
etic changes.
In addition, human RPE cells have specific properties
that are not found in currently available cell lines such as
ARPE19. Human RPE cells have been generated from em-
bryonic stem cells (ESCs) and iPS cells offering new prom-
ise for cell replacement therapy in AMD [13,15,18,70].
Stem cell biology may offer a breakthrough method for
creating disease models that demonstrate the pathology of
AMD in detail. Understanding the development and pro-
gression of AMD will likely offer new insight for devel-
opment of potential therapies. In addition, a recent
study showed that adult human RPE might contain a
subpopulation of cells that are capable of self-renewal
and can produce mesenchymal derivatives [71]. This
observation could open new avenues for treatment ofretinal degeneration by activating the dormant stem
cells in the RPE.
Current procedures & ramifications
Current treatment options in AMD can only hope to
slow the progression of disease, although a recent review
of the literature suggests that the field of AMD therapy
is dynamically changing and growing rapidly, with some
strategies seeking to correct the damage of AMD [72].
Most therapies that are currently utilized in the clinic
have shown mild success in slowing degeneration of RPE
and preventing the onset of neovascularization. Laser
therapy has been shown to significantly reduce drusen
accumulation in patients with dry AMD within a three-
month period post-operation [73]. However despite the
overall reduction in drusen with this laser photocoagulation,
the risk of later developing choroidal neovascularization
(CNV), geographic atrophy, or loss of central vision is not
reduced [74]. In fact, studies have shown that patients given
higher intensity laser therapy are at a higher risk of develop-
ing choroidal neovascularization [75].
Anti-angiogenic therapies are currently FDA-approved
for neovascular AMD, with clinical trials showing signifi-
cant improvement in visual acuity and slowed progres-
sion of disease [76]. It has been shown that patients with
neovascularization demonstrate abnormally high levels
of VEGF-A in the choroidal layer and vitreous humor
and that this expression contributes greatly to the
growth and proliferation of immature capillaries [77,78].
These vessels demonstrate abnormal capillary lumens
and increased permeability, making them particularly
susceptible to spontaneous hemorrhage, thereby causing
significant macular damage [77,78] . The anti-VEGF
treatment helps to decrease the formation of new vessels
and prevent further infiltration of the choroidal layer
into the nearby RPE. Numerous studies have shown clin-
ical efficacy for ranibizumab and bevacizumab, monoclo-
nal antibodies that specifically bind VEGF-A [79,80].
Both antibodies have demonstrated efficacy in slowing
vision loss and improving visual acuity [81,82]. However,
some serious side effects have been noted including
macular hemorrhages and retinal detachment [83].
A surgical technique has also been designed for treat-
ment of AMD involving the partial or total translocation
of the macula to area of less diseased RPE [84,85]. This
approach has resulted in improved visual acuity for a
percentage of patients, however it presents significant
complications, including fibrosis and widespread failure
of RPE survival on Bruch’s membrane despite minimal im-
provements in vision, bleeding, corneal astigmatism, and
retinal detachment with proliferative vitreoretinopathy
[86-88]. Many patients also experience tilting of the visual
image or diplopia after retinal rotation [84]. Given the
complications associated with the surgical procedures,
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the concept of utilizing a healthy RPE layer persists and
has inspired the implantation of non-diseased RPE cells
derived from donors and stem cell-based therapies for re-
placement of the disease cells in the retina.
Cellular transplant as therapy for AMD
AMD is initiated with the dysfunction and death of RPE,
leading to photoreceptor loss and significant deficits in
vision. Therefore, the key in successful cell-based ther-
apy in AMD would be early replacement of the damaged
RPE [21]. Several studies have shown that transplanted
RPE cells have the potential to rescue photoreceptors
[89-91]. To date, a number of studies have investigated
various stem cell types as potential sources for retinal
transplantation including ESCs, adult stem/progenitor
cells and more recently induced pluripotent stem cells
(iPSCs) [92-94]. Use of stem cells for retinal repair offers
enormous promise for generation of adequate and appro-
priate cell populations for transplantation. Subretinally
transplanted RPE that were differentiated from ESCs have
led to improvements in visual acuity in preclinical models
of the disease [16,70] In addition, human iPSCs have been
differentiated towards functional RPE cells, and we have
demonstrated that human iPSC-derived RPE are function-
ally and phenotypically similar to native RPE [18]. Unfor-
tunately, the subretinal transplantation of RPE cell
suspensions in the Royal College of Surgeons (RCS) rat
model, a genetic model of RPE degeneration, has only
resulted in short-term survival and maintenance of photo-
receptors [14]. Therefore, the efficiency of cell delivery
and the degree of visual rescue often remain unsatisfac-
tory, despite the apparently positive findings [95-97]. This
lack of efficacy may be due to a number of reasons: 1)
RPE cells are adherent monolayer cells and therefore must
attach to a compliant matrix following transplantation, 2)
the basal lamina layer of Bruch’s membrane may be dam-
aged or absent in advanced retinal disease, with age, or
following macular surgery [98], lacking the supportive
structure upon which RPE cells are normally attached;
thus, it is difficult for newly transplanted cells to attach in
such a non-tolerant environment, 3) transplanted cells
may clump together rather than forming appropriately po-
larized monolayer RPE [99]. Furthermore, lack of cell-to-
cell contact may also lead to transition of RPE cells to
inappropriate phenotypes such as epithelial-mesenchymal
transition [97,100].
Therefore, the gap between theory and clinical exploit-
ation remains considerable [101,102]. In addition, safe
and efficient tissue delivery needs to be considered, as
do survival and integration of the transplanted cells
within the host [103-105]. Any transplanted material
must also be capable of maintaining an appropriate state
of differentiation. In addition, immune surveillance is asignificant issue, and so the approach of autologous
sources of cells for transplantation to negate problems
with graft rejection would be ideal [106].
Biomaterials and cell delivery scaffolds
It has been documented that cells injected as a suspen-
sion often fail to survive and to regain a fully differenti-
ated phenotype [90,107]. In addition, the viability of RPE
cells delivered to the subretinal space is often dependent
on the integrity of the underlying substrate, the Bruch’s
membrane [108,109]. Thus, transplantation of a polar-
ized RPE monolayer as a sheet seems to be more prom-
ising. Studies have shown that scaffolds made of
biodegradable polyester such as poly (L-lactic acid)
(PLLA) and poly (D, L-lactic-co-glycolic acid) (PLGA)
could improve cell survival and organization of retinal
progenitor cells (RPCs) and promote differentiation of
the RPCs towards mature retinal cell phenotypes [110].
These polymers were selected, as they are biocompatible,
relatively easy to process and have been successfully
used for tissue engineering applications [111,112]. The
degradation rate of these polymers can also be manipu-
lated by changing properties such as molecular weight
and the ratio of lactic to glycolic units. Thus, polymers
can be designed to degrade over the most appropriate
timescale for the desired application. Several other poly-
mers and preparation techniques have also been investi-
gated. Many factors such as surface chemistry,
mechanical properties and surface topology can affect
the practicability of different materials for cell attach-
ment and survival. Examples of other polymers are: Poly
(methyl methacrylate) (PMMA) that has been used to
manufacture ultrathin, micro-machined scaffolds for
RPCs [113]. Similarly, poly (glycerol sebacate) (PGS)
[114-116] has been used to manufacture a porous,
elastic scaffold and poly (ε-caprolactone) (PCL) [117] to
produce ultrathin nanowire scaffolds. These polymers
have supported successful growth of murine retinal pro-
genitor cells both in vitro and in vivo in degenerative
mouse models.
Stem cells in AMD
Human embryonic stem cells
Human embryonic stem (hES) cells have dramatically al-
tered the field of cellular biology since the first lines
were established in 1998 [10]. With regard to retinopa-
thies like AMD and Stargardt disease, these cells have
shown commitment to RPE formation in vitro in re-
sponse to culturing techniques that direct differentiation
towards the RPE lineage [16,118-121]. Furthermore,
in vivo subretinal transplant of purified hESC-derived
RPEs into the Royal College of Science (RCS) rat and
the Elov14 mouse, an animal model for Stargardt dis-
ease, have shown marked improvements in visual
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formation or cellular hyperproliferation [14,16].
Although these data are promising, the use of hESCs
is challenging due to the ethical issues, the immuno-
logical reaction and the long-term risks of teratoma for-
mation [10]. The field continues to improve culturing
techniques for hESC-RPEs by reducing the need for co-
culture or animal growth factors [122]. HESCs express
human leukocyte markers (HLA) that mediate immune
responses, thus making hESC-RPE grafts susceptible to
rejection response by the recipient, despite relative
immune-privilege in the subretinal space. Therefore
therapies using hESCs require administration of im-
munosuppressive drugs that may induce complications
in elderly patients.
The limited available number of hESC cell lines tends
to limit the quality of these cultured cells, particularly
with extended culture and expansion, which results in a
decline of surface receptors, enzymatic activity and over-
all loss of cellular polarization in hESC-RPE differenti-
ated lines [123]. Efforts to develop refined culturing
technique, and methods for the necessary large-scale ex-
pansion of these delicate cell populations must be ex-
plored before hESC therapy can become a reality for
patients with AMD. However the ethical concerns will
always limit the use of ESCs at least in certain countries.
Induced pluripotent stem (iPS) cells
Recent studies have shown that the donor cell type can
influence the epigenome and differentiation potential of
iPSCs [124-132]. For example, non-hematopoetic iPCs
will show a less robust differentiation towards blood
cells than those that were originally of hematopoetic ori-
gin and vice versa, likely due to repressive methylation
patterns that persist at loci necessary for commitment to
that particular lineage [127]. Moreover, it has been shown
that human iPSCs derived from RPE (RPE-derived iPSCs)
retain the epigenetic memory of their tissue of origin
(RPE) [133]. Understanding the dynamics and implica-
tions of this biology is necessary prior to implementation
of iPSC therapies in human subjects to accurately predict
outcome and reduce risk.
Future directions of stem cell therapy in AMD
Perhaps among the most promising clinical stem cell study
to date is a very small Phase I clinical trial in treatment of
AMD with transplant of hESC-RPEs (NCT01344993).
These patients received a cellular suspension graft of >99%
purified hESC-RPEs injected into the subretinal space.
Four months following transplant, neither patient showed
formation of teratoma or tumor at the site of injection and
both reported improved visual acuity, although placebo ef-
fect has not been assessed. This trial utilized minimum cell
numbers in transplant which has been shown to reducelikelihood of teratoma formation and also secured an
extraordinarily high level of hESC-RPE purity, thus redu-
cing the possibility of aberrant differentiation of cells that
had retained pluripotency. Results from this small clinical
experiment are to be met with conservative enthusiasm,
given the very limited sample size and modest benefit. At
this time, the trial will be expanded to a greater cohort of
patients, with the results anticipated in January/June 2013.
This open-label Phase I/II trial seeks to determine the
safety and tolerability of this procedure and represents one
of the first clinical trials involving the use of stem cell
transplant in treatment of macular dystrophy and related
retinopathies [134].
RPE transplantation for the neuroprotection of retinal
photoreceptors within the retina in AMD is among the
first application of hESC transplant clinically. Restor-
ation of an intact RPE layer will likely prevent progres-
sion and further deterioration of the photoreceptors,
improving the microenvironment needed for survival of
the remaining retinal cells. HESCs and iPSCs have suc-
cessfully been differentiated into functional RPE and
photoreceptors in vitro [15,18,121,135]. Application of
these cultures may be successful in the future after devel-
opment of more advanced techniques in transplant and
scaffolding. In vivo models of photoreceptor dysfunction,
particularly the Crx-deficient (cone-rox homeobox) mouse
model, responds to photoreceptor transplant with integra-
tion of hESC-photoreceptors into the subretinal space
and increased responses to light stimuli [135]. Photo-
receptor transplant in macular degeneration may also
confer a great therapeutic avenue in the future for rescue
visual acuity.
Conclusions
The wealth of data from stem cell-derived RPE in
disease-models and clinical trials will undoubtedly yield
important insight in understanding the mechanisms of
AMD and developing effective treatment strategies. The
iPS-derived RPE opens new avenues for generation of a
“disease in a dish” model of AMD that otherwise would
not be possible to recreate. For cell transplantations,
concerns remain regarding the process of pluripotency
induction and residual epigenetics in iPS cells, particu-
larly since there are unique characteristics that may sig-
nificantly affect the propensity of differentiation and
may influence ongoing attempts to use iPSCs for disease
modeling. Human embryonic stem cells also present
dangers associated with teratoma formation, which must
be understood and controlled prior to implementation
of successful wide-scale clinical trial. Consequently,
identifying and understanding the markers of disease
and therapeutic response by generating an in vitro dis-
ease model of AMD will undoubtedly yield more in-
novative therapeutics that will target the etiology of
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time, efforts to maximize RPE survival and integration at
the subretinal region are paramount for success of this
therapeutic strategy.
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